What is it about?

Intravenous ketamine has rapid-acting antidepressant properties, but these effects typically dissipate quickly in the absence of repeated infusions. Here we present novel evidence that a fully automated, computer-based approach can efficiently extend the duration of rapid clinical response among depressed patients following a single ketamine infusion.

Featured Image

Read the Original

This page is a summary of: A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial, American Journal of Psychiatry, December 2022, American Psychiatric Association,
DOI: 10.1176/appi.ajp.20220216.
You can read the full text:

Read

Contributors

The following have contributed to this page